title: Should ethnicity serve as the basis for clinical trial design? Importance of race/ethnicity in clinical trials: lessons from the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
authors.affiliation: National Center of Excellence in Women's Health, University of Minnesota Medical School, Minneapolis, MN 55455, USA. taylo135@umn.edu
authors.forename: Anne L
authors.initials: AL
authors.lastname: Taylor
authors.forename: Jackson T
authors.initials: JT
authors.lastname: Wright
mesh_terms: D001741:Black or African American; D000959:Antihypertensive Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000379:methods*; D005006:Ethnicity; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D006977:Hypertension, Renal; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007674:Kidney Diseases / Q000150:complications / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000517:prevention & control*; D044469:Racial Groups
chemical_list: D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents